Amalgamated Bank’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,637
| Closed | -$262K | – | 2576 |
|
|
2025
Q4 | $262K | Buy |
3,637
+333
| +10% | +$21.5K | ﹤0.01% | 1506 |
|
|
2025
Q3 | $144K | Sell |
3,304
-611
| -16% | -$24.7K | ﹤0.01% | 1643 |
|
|
2025
Q2 | $111K | Hold |
3,915
| – | – | ﹤0.01% | 1679 |
|
|
2025
Q1 | $116K | Buy |
3,915
+418
| +12% | +$13K | ﹤0.01% | 1645 |
|
|
2024
Q4 | $102K | Hold |
3,497
| – | – | ﹤0.01% | 1697 |
|
|
2024
Q3 | $161K | Hold |
3,497
| – | – | ﹤0.01% | 1623 |
|
|
2024
Q2 | $143K | Buy |
3,497
+982
| +39% | +$28.2K | ﹤0.01% | 1641 |
|
|
2024
Q1 | $64K | Sell |
2,515
-3,682
| -59% | -$57.7K | ﹤0.01% | 1812 |
|
|
2023
Q4 | $56K | Sell |
6,197
-709
| -10% | -$4.74K | ﹤0.01% | 2194 |
|
|
2023
Q3 | $44K | Hold |
6,906
| – | – | ﹤0.01% | 2308 |
|
|
2023
Q2 | $77K | Hold |
6,906
| – | – | ﹤0.01% | 2152 |
|
|
2023
Q1 | $106K | Buy |
6,906
+6
| +0.1% | +$132 | ﹤0.01% | 2038 |
|
|
2022
Q4 | $153K | Buy |
6,900
+285
| +4% | +$4.25K | ﹤0.01% | 1953 |
|
|
2022
Q3 | $108K | Buy |
6,615
+425
| +7% | +$8.13K | ﹤0.01% | 2116 |
|
|
2022
Q2 | $90K | Buy |
6,190
+1,381
| +29% | +$20.5K | ﹤0.01% | 2209 |
|
|
2022
Q1 | $89K | Buy |
+4,809
| New | +$81.7K | ﹤0.01% | 2241 |
|
Other funds holding RNAM
Amalgamated Bank's RNAM Position: Q1 2026 in Review
Amalgamated Bank sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,637 shares — an estimated $262K sold.
Amalgamated Bank first reported a position in RNAM in Q1 2022 and held it in 16 quarters. The position peaked at $262K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Amalgamated Bank reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Amalgamated Bank sold 3,637 Avidity Biosciences shares in Q1 2026, an estimated $262K.
- Amalgamated Bank first reported a position in Avidity Biosciences in Q1 2022 and held it in 16 quarters.
- Amalgamated Bank's Avidity Biosciences position peaked at $262K in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.